Kardigan, Inc.

NASDAQ:KARD

Biotechnology

Healthcare
$12.32 +3.50%

+$0.77 today

Market cap
$1.10B
Beta
0.00
52W Low $16.25High $24.00

Volume 0.55M

Average 5.84M

KARD Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

No reported Research & Development figures are available to summarize.

Research & Development history

Currency unavailable · from the income statement

No Research & Development data reported for this period type.

Research & Development vs competitors

How KARD compares with its peers on the latest reported figures

KARD Competitors
Research & Development for KARD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CYTKCytokinetics, IncorporatedLTM Jun 2026$394.1M USD+0.9%+19.0%555.4%
NAMSNewAmsterdam Pharma Company N.V.LTM Jun 2026$148.75M USD+4.1%+17.8%2088.9%
TNYATenaya Therapeutics, Inc.LTM Mar 2026$62.37M USD-24.6%-10.1%27721.8%
RNAAtrium Therapeutics, Inc.FY2025$53.76M USD——288.7%
IKTInhibikase Therapeutics, Inc.LTM Mar 2026$30.12M USD+20.6%+35.3%—
KARDKardigan, Inc.—— ———
Peer median (excluding KARD) —+2.5%+18.4%1322.1%

Competitors are the stored peer set for KARD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Kardigan, Inc.

NASDAQ:KARD

Intrinsic Alpha fair value

Locked

Current Price

$12.32

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.